Digital Content 
NEWS #PharmaBuzz
28 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/28/3051280/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-treatment-of-patients-with-moderately-to-severely-active-Crohn-s-Disease.html
21 Mar 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/jj-advances-stelara-succession-scheme-key-fda-nod-tremfya-crohns-disease
28 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/28/3034748/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis.html
21 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/tremfya-guselkumab-subcutaneous-sc-induction-data-support-potential-to-be-the-first-and-only-in-its-class-to-offer-the-option-of-both-intravenous-and-sc-induction-therapy-in-ulcerative-colitis-302381823.html
03 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/johnson--johnson-seeks-us-fda-approval-for-first-pediatric-indications-for-tremfya-guselkumab-302317847.html
02 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/johnson--johnson-seeks-us-fda-approval-for-first-pediatric-indications-for-tremfya-guselkumab-302317847.html
Share 